Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis

Research in Veterinary Science

Volumn 95, Issue 2, 2013, Pages 580-587

  Fink, M ^a   Letellier, I ^b   Peyrou, M ^c   Mochel, J P ^a,c   Jung, M ^c   King, J N ^a   Gruet, P ^a   Giraudel, J M ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Sante Animale SAS   (France)

^c Centre de Recherche Sante Animale   (Switzerland)

^d Novartis Animal Health Australasia Pty Ltd   (Australia)

Author keywords

COXIB; Dog; Population pharmacokinetics; Robenacoxib

Indexed keywords

ROBENACOXIB;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; MALE; MULTICENTER STUDY; NONHUMAN; OSTEOARTHRITIS; POPULATION RESEARCH; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

CANIS FAMILIARIS;

AREA UNDER THE CURVE; AUC; BELOW LIMIT OF QUANTIFICATION; BLQ; COX; COXIB; CYCLOOXYGENASE; DOG; EBES; EMPIRICIAL BAYES ESTIMATES; FIRST ORDER CONDITIONAL ESTIMATION METHOD; FOCE; IIV; INTER-INDIVIDUAL VARIABILITY; INTER-OCCASION VARIABILITY; IOV; LLOQ; LOWER LIMIT OF QUANTIFICATION; NON-STEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; OA; OBJECTIVE FUNCTION VALUE; OFV; OSTEOARTHRITIS; POPULATION PHARMACOKINETICS; RELATIVE STANDARD ERROR; ROBENACOXIB; RSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CHRONIC DISEASE; DIPHENYLAMINE; DOG DISEASES; DOGS; FEMALE; MALE; OSTEOARTHRITIS; PHENYLACETATES; SEX FACTORS;

EID: 84881556106     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2013.04.021     Document Type: Article

References (17)

1. Beal S.L. Ways to fit a PK model with some data below the quantification limit. Journal of Pharmacokinetics and Biopharmaceutics 2001, 28(5):481-504.
2. Bergstrand M., Karlsson M.O. Handling data below limit of quantification in mixed effect models. AAPS Journal 2009, 11(2):371-380.
3. Cox S.R., Liao S., Payne-Johnson M., Zielinski R.J., Stegemann M.R. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. Journal of Veterinary Pharmacology and Therapeutics 2011, 34(1):1-11.
4. Fleischer S., Sharkey M., Mealey K., Ostrander E.A., Martinez M. Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS Journal 2008, 10(1):110-119.
5. Gruet P., Seewald W., King J.N. Evaluation of subcutaneous and oral administration of robenacoxib and meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs. American Journal of Veterinary Research 2011, 72(2):184-193.
6. Jonsson E.N., Karlsson M.O. Xpose - an S-plus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine 1999, 58(1):51-64.
7. Jung M., Lees P., Seewald W., King J.N. Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of Veterinary Pharmacology and Therapeutics 2009, 32(1):41-48.
8. King J.N., Arnaud J.P., Goldenthal E.I., Gruet P., Jung M., Seewald W., Lees P. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. Journal of Veterinary Pharmacology and Therapeutics 2011, 34(3):298-311.
9. King J.N., Dawson J., Esser R.E., Fujimoto R., Kimble E.F., Maniara Lees.P. Pre-clinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. Journal of Veterinary Pharmacology and Therapeutics 2009, 32(1):1-17.
10. King J.N., Rudaz C., Borer L., Jung M., Seewald W., Lees P. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Research in Veterinary Science 2010, 88(3):497-506.
11. Martinez M., Mahmood I., Hunter R.P. Allometric scaling of clearance in dogs. Journal of Veterinary Pharmacology and Therapeutics 2009, 32(5):411-416.
12. Paulson S.K., Engel L., Reitz B., Bolten S., Burton E.G., Maziasz T.J., Schoenhard G.L. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metabolism and Disposition 1999, 27(10):1133-1142.
13. Reymond N., Speranza C., Gruet P., Seewald W., King J.N. Robenacoxib versus carprofen for the treatment of canine osteoarthritis; a randomized, non-inferiority field study. Journal of Veterinary Pharmacology and Therapeutics 2012, 35(2):175-183.
14. Rordorf C.M., Choi L., Marshall P., Mangold J.B. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics 2005, 44(12):1247-1266.
15. Schmid V.B., Spreng D.E., Seewald W., Jung M., Lees P., King J.N. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in the dog. Journal of Veterinary Pharmacology and Therapeutics 2010, 33(2):118-131.
16. Silber H.E., Burgener C., Letellier I.M., Peyrou M., Jung M., King J.N., Gruet P., Giraudel J.M. Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharmaceutical Research 2010, 27(12):2633-2645.
17. Wählby U., Jonsson E.N., Karlsson M.O. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS Pharmaceutical Science 2002, 4(4):E27.